Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma

Seminars in Hematology
Trevor J Pugh

Abstract

Circulating tumor DNA faithfully recapitulates somatic mutations detected in bone marrow aspirates from patients with newly diagnosed or relapsed or recurrent myeloma. Extending these methods to enable detection of minimal residual disease will require increased sensitivity and breadth of genomic assays to maximize information content from small quantities of cell-free DNA; as well as definition of a clinically meaningful ctDNA concentration in comparison with conventional bone marrow cell-count thresholds. This review describes the use of cell-free DNA sequencing in myeloma to date, identifies challenges associated with pushing limit of detection of these assays into the realm of detecting minimal residual disease, and describes potential strategies to overcome these challenges.

Citations

Dec 6, 2018·Molecular Oncology·Lisanne F van DesselMartijn P Lolkema
Jan 24, 2019·Current Hematologic Malignancy Reports·Shalin KothariSarah A Holstein
Aug 1, 2019·British Journal of Haematology·Susan BalLuciano J Costa
Jul 23, 2020·Frontiers in Oncology·Cristina TurcasCiprian Tomuleasa
Apr 5, 2020·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Bruna FerreiraCristina João
Mar 10, 2021·Skeletal Radiology·Megan J FitzpatrickAliyah R Sohani
Jul 30, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenneth C AndersonShaji K Kumar
Apr 18, 2019·Acta Cytologica·Robyn Sussman, Jason N Rosenbaum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.